Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy

Condition:   Asthma
Interventions:   Drug: Respimat® Budesonide low dose;   Drug: Respimat® Budesonide high dose;   Drug: Turbohaler® Budesonide;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Completed – verified July 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

For Severe Asthma, Most Surveyed U.S. Payers Would Reimburse a Novel … – PR Newswire (press release)

For Severe Asthma, Most Surveyed U.S. Payers Would Reimburse a Novel
PR Newswire (press release)
Surveyed U.S. and European pulmonologists agree that reduction in rate of exacerbations is the attribute that most influences prescribing decisions in moderate to severe asthma. Clinical data and the opinions of interviewed thought leaders indicate

View full post on asthma – Google News